A few other indications have also been identified for protein-protein interaction modulators, like anti-angiogenesis for p300-HIF-1α [89] as well as type II diabetes for CREB (cAMP response element-binding protein)-CBP (CREB-binding protein) interaction [90]. This evidence concerns the gene CREBBP and type 2 diabetes mellitus.